Terms: = Lung cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Prognosis
64 results:
1. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.
Ma C; Gu Z; Yang Y
J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237
[TBL] [Abstract] [Full Text] [Related]
2. Deciphering disulfidptosis: Uncovering a lncRNA-based signature for prognostic assessment, personalized immunotherapy, and therapeutic agent selection in lung adenocarcinoma patients.
Ma C; Zhao H; Sun Y; Ding W; Wang H; Li Y; Gu Z
Cell Signal; 2024 May; 117():111105. PubMed ID: 38369264
[TBL] [Abstract] [Full Text] [Related]
3. Pan-cancer analysis of homeodomain-containing gene C10 and its carcinogenesis in lung adenocarcinoma.
Tan X; Li Z; Xie H; Chen J; Xiao J; Zhi Y; Mo H; Huang Y; Liu A
Aging (Albany NY); 2023 Dec; 15(24):15243-15266. PubMed ID: 38154103
[TBL] [Abstract] [Full Text] [Related]
4. Crosstalk between copper homeostasis and cuproptosis reveals a lncRNA signature to prognosis prediction, immunotherapy personalization, and agent selection for patients with lung adenocarcinoma.
Ma C; Gu Z; Ding W; Li F; Yang Y
Aging (Albany NY); 2023 Nov; 15(22):13504-13541. PubMed ID: 38011277
[TBL] [Abstract] [Full Text] [Related]
5. Down-regulation of interleukin-2 predicts poor prognosis and associated with immune escape in lung adenocarcinoma.
Hou Y; Xiang B; Yang Z; Liu J; Xu D; Geng L; Zhan M; Xu Y; Zhang B
Int J Immunopathol Pharmacol; 2023; 37():3946320231202748. PubMed ID: 37731383
[No Abstract] [Full Text] [Related]
6. cancer-associated fibroblasts drive CXCL13 production in activated T cells via TGF-beta.
O'Connor RA; Martinez BR; Koppensteiner L; Mathieson L; Akram AR
Front Immunol; 2023; 14():1221532. PubMed ID: 37520560
[TBL] [Abstract] [Full Text] [Related]
7. Identifying potential targets for lung cancer intervention by analyzing the crosstalk of cancer-associated fibroblasts and immune and metabolism microenvironment.
Wei S; Bao M; Zhu Y; Zhang W; Jiang L
Environ Toxicol; 2023 Aug; 38(8):1951-1967. PubMed ID: 37186041
[TBL] [Abstract] [Full Text] [Related]
8. Multi-omic and spatial dissection of immunotherapy response groups in non-small cell lung cancer.
Monkman J; Kim H; Mayer A; Mehdi A; Matigian N; Cumberbatch M; Bhagat M; Ladwa R; Mueller SN; Adams MN; O'Byrne K; Kulasinghe A
Immunology; 2023 Aug; 169(4):487-502. PubMed ID: 37022147
[TBL] [Abstract] [Full Text] [Related]
9. Resveratrol improves the cytotoxic effect of CD8 +T cells in the tumor microenvironment by regulating HMMR/Ferroptosis in lung squamous cell carcinoma.
Shan G; Minchao K; Jizhao W; Rui Z; Guangjian Z; Jin Z; Meihe L
J Pharm Biomed Anal; 2023 May; 229():115346. PubMed ID: 37001272
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic Value of EMT Gene Signature in Malignant Mesothelioma.
Wu L; Yoshihara K; Yun H; Karim S; Shokri N; Zaeimi F; Man HSJ; Zia A; Felley-Bosco E; de Perrot M
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901697
[TBL] [Abstract] [Full Text] [Related]
11. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract] [Full Text] [Related]
12. Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells.
Noyes D; Bag A; Oseni S; Semidey-Hurtado J; Cen L; Sarnaik AA; Sondak VK; Adeegbe D
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618289
[TBL] [Abstract] [Full Text] [Related]
13. NEDD4L suppresses PD-L1 expression and enhances anti-tumor immune response in A549 cells.
Zhong B; Zheng J; Wen H; Liao X; Chen X; Rao Y; Yuan P
Genes Genomics; 2022 Sep; 44(9):1071-1079. PubMed ID: 35353342
[TBL] [Abstract] [Full Text] [Related]
14. Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25
Chen Z; Yang Y; Neo SY; Shi H; Chen Y; Wagner AK; Larsson K; Tong L; Jakobsson PJ; Alici E; Wu J; Cao Y; Wang K; Liu LL; Mao Y; Sarhan D; Lundqvist A
EMBO Rep; 2021 Mar; 22(3):e51329. PubMed ID: 33480074
[TBL] [Abstract] [Full Text] [Related]
15. Dynamic biomarkers indicate the immunological benefits provided by Ganoderma spore powder in post-operative breast and lung cancer patients.
Deng Y; Ma J; Tang D; Zhang Q
Clin Transl Oncol; 2021 Jul; 23(7):1481-1490. PubMed ID: 33405051
[TBL] [Abstract] [Full Text] [Related]
16. Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer.
Lim JU; Yoon HK
Cytokine; 2021 Feb; 138():155363. PubMed ID: 33264749
[TBL] [Abstract] [Full Text] [Related]
17. Changes in serum inflammatory factors, adiponectin, intestinal flora and immunity in patients with non-small cell lung cancer.
Wang RP; Wang XH; Li ZM; Sun JR
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10566-10572. PubMed ID: 33155213
[TBL] [Abstract] [Full Text] [Related]
18. Effect of asbestos exposure on differentiation and function of cytotoxic T lymphocytes.
Kumagai-Takei N; Nishimura Y; Maeda M; Hayashi H; Matsuzaki H; Lee S; Yoshitome K; Ito T; Otsuki T
Environ Health Prev Med; 2020 Oct; 25(1):59. PubMed ID: 33032525
[TBL] [Abstract] [Full Text] [Related]
19. NK cells in the tumor microenvironment and thioredoxin activity.
Whiteside TL
J Clin Invest; 2020 Oct; 130(10):5115-5117. PubMed ID: 32925168
[TBL] [Abstract] [Full Text] [Related]
20. Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial.
Multhoff G; Seier S; Stangl S; Sievert W; Shevtsov M; Werner C; Pockley AG; Blankenstein C; Hildebrandt M; Offner R; Ahrens N; Kokowski K; Hautmann M; Rödel C; Fietkau R; Lubgan D; Huber R; Hautmann H; Duell T; Molls M; Specht H; Haller B; Devecka M; Sauter A; Combs SE
Clin Cancer Res; 2020 Oct; 26(20):5368-5379. PubMed ID: 32873573
[TBL] [Abstract] [Full Text] [Related]
[Next]
